Join Adrian Dawkes, Managing Director at PharmaVentures, for this podcast episode exploring how the pharmaceutical manufacturing sector is evolving in response to shifting global pressures. Our experts, Ross Jenkins and Dr Gurdas Singh, unpack the critical changes shaping the industry.
Listen here:
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
About the Interviewees:
Ross Jenkins joined PharmaVentures as a Business Analyst and has since been promoted to Director, with previous experience in diagnostic start-ups and commercialisation.
Prior to joining PharmaVentures, Ross worked at a multiplex immune-diagnostic start-up in New Zealand focused on both human and animal health. During this time he was involved across all areas of the business from communications, manufacturing, quality/regulatory affairs, and market analysis. Ross holds a BSC(Hons) in Biotechnology and, a PGDip and Masters in Bioscience Enterprise from the University of Auckland.
Dr Gurdas Singh advises on both buy-side and sell-side transactions globally. He specialises in guiding companies to optimise their positioning for partnerships and M&A opportunities across diagnostics, pharmaceutical manufacturing, and healthcare services.
Gurdas holds a Master’s of Research from The University of Oxford, securing multiple research grants and having authored over 20 publications. He also earned a Bachelor’s of Medicine and Surgery (MBBS) and a Bachelor’s of Science in Medical Sciences from King’s College London.
In this podcast, PharmaVentures explores the recent changes in the landscape of Drug Pricing. This episode delves into the evolving differences between Europe and the US and how it has an impact on both. It also assesses the how Direct-to-Patient strategies, now being deployed by pharmaceutical companies in the US, can change the cost to the patient.
Listen here:
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
About the Interviewee:
Samara Ferguson is Vice President at PharmaVentures, leading its Pricing and Market Access division, supporting companies in their sell-side, buy-side, and licensing due diligence and deal-making.
For over 20 years, Samara has held multiple roles in the pharmaceutical industry, giving her a unique insight and experience in market access, health economics and outcomes research. Samara’s consultancy experience also brings many years of insight across numerous therapy areas, where she rigorously pressure-tested market access and price potential, developed market access strategies, evidence generation plans, and bespoke real-world studies. Samara holds a MSc in Health Economics and Health Policy from the University of Birmingham.
H1 2025: Acceleration, Integration, and the Shift from Innovation to Infrastructure
H1 2025 saw sustained Dx deal activity, highlighting sector resilience despite macroeconomic headwinds. We identified a total deal volume of 174 across Q1 and Q2, which was stable year-over-year (vs. 171 in H1 2024), but deal composition signalled a strategic shift.
The US biopharma VC landscape has been transformed over the last four years. The free-flowing capital of the pandemic sugar rush era peaked in Q4 2020, after which the IPO window snapped firmly shut in the last quarters of 2022. The next year for biotech was even worse in most respects: IPOs down, VC down, M&A down, licensing deals down. However, despite lower deal numbers and total capital deployment, reported valuations appeared to hold firm and start recovering in late 2023. This white paper provides insightful and in-depth analysis of the US biopharma VC landscape.
